https://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.png00David Andersonhttps://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.pngDavid Anderson2019-09-24 05:00:442019-09-23 21:18:00Amplyx Announces Presentations on Fosmanogepix (APX001) at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9)
https://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.png00eallisonhttps://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.pngeallison2019-09-16 11:08:172019-09-16 11:08:54Amplyx Pharmaceuticals Licenses Phase 2 Drug Candidate for BK Viral Disease in Transplant Patients
https://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.png00eallisonhttps://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.pngeallison2019-09-16 11:06:362019-09-16 11:09:16Amplyx Pharmaceuticals Announces Positive Preliminary Data from Ongoing Fosmanogepix Phase 2 Study in Candidemia
https://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.png00David Andersonhttps://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.pngDavid Anderson2019-09-09 05:00:122019-09-09 10:15:06FDA Grants Fast Track Status to Amplyx Pharmaceuticals for IV and Oral Formulations of Fosmanogepix (APX001) for Seven Different Indications
https://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.png00Lauren Fishhttps://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.pngLauren Fish2019-04-12 05:48:132019-04-12 05:48:13Amplyx Pharmaceuticals Announces Presentations at the 29th ECCMID in Amsterdam
https://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.png00jnellishttps://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.pngjnellis2019-02-11 06:12:262019-02-11 06:12:26FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis
https://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.png00jnellishttps://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.pngjnellis2019-01-31 15:12:552019-01-31 15:12:55Antimicrobials Working Group Announces Updates to Leadership Team
https://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.png00jnellishttps://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.pngjnellis2018-11-12 16:35:132018-11-12 16:35:13Amplyx Doses First Patient in Phase 2 Trial of APX001 in Patients with Candida Infection
https://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.png00jnellishttps://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.pngjnellis2018-06-07 05:00:222018-06-07 14:00:34Amplyx Announces Presentations on APX001 at American Society for Microbiology Microbe 2018 and the 20th Symposium on Infections in the Immunocompromised Host
https://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.png00jnellishttps://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.pngjnellis2018-06-05 05:12:532018-06-05 05:14:21Amplyx Pharmaceuticals to Participate in BIO International Convention Panel and Present at Jefferies Global Healthcare Conference
